176 related articles for article (PubMed ID: 21953882)
1. Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors.
Fichna J; Dicay M; Lewellyn K; Janecka A; Zjawiony JK; MacNaughton WK; Storr MA
Inflamm Bowel Dis; 2012 Jun; 18(6):1137-45. PubMed ID: 21953882
[TBL] [Abstract][Full Text] [Related]
2. Novel orally available salvinorin A analog PR-38 protects against experimental colitis and reduces abdominal pain in mice by interaction with opioid and cannabinoid receptors.
Sałaga M; Polepally PR; Zakrzewski PK; Cygankiewicz A; Sobczak M; Kordek R; Zjawiony JK; Krajewska WM; Fichna J
Biochem Pharmacol; 2014 Dec; 92(4):618-26. PubMed ID: 25265540
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors.
Capasso R; Borrelli F; Cascio MG; Aviello G; Huben K; Zjawiony JK; Marini P; Romano B; Di Marzo V; Capasso F; Izzo AA
Br J Pharmacol; 2008 Nov; 155(5):681-9. PubMed ID: 18622408
[TBL] [Abstract][Full Text] [Related]
4. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice.
Cluny NL; Keenan CM; Duncan M; Fox A; Lutz B; Sharkey KA
J Pharmacol Exp Ther; 2010 Sep; 334(3):973-80. PubMed ID: 20571060
[TBL] [Abstract][Full Text] [Related]
5. Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating kappa-opioid and cannabinoid receptors.
Fichna J; Schicho R; Andrews CN; Bashashati M; Klompus M; McKay DM; Sharkey KA; Zjawiony JK; Janecka A; Storr MA
Neurogastroenterol Motil; 2009 Dec; 21(12):1326-e128. PubMed ID: 19650775
[TBL] [Abstract][Full Text] [Related]
6. Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis.
Engel MA; Kellermann CA; Burnat G; Hahn EG; Rau T; Konturek PC
J Physiol Pharmacol; 2010 Feb; 61(1):89-97. PubMed ID: 20228420
[TBL] [Abstract][Full Text] [Related]
7. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment.
Schicho R; Bashashati M; Bawa M; McHugh D; Saur D; Hu HM; Zimmer A; Lutz B; Mackie K; Bradshaw HB; McCafferty DM; Sharkey KA; Storr M
Inflamm Bowel Dis; 2011 Aug; 17(8):1651-64. PubMed ID: 21744421
[TBL] [Abstract][Full Text] [Related]
8. Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.
Sałaga M; Polepally PR; Sobczak M; Grzywacz D; Kamysz W; Sibaev A; Storr M; Do Rego JC; Zjawiony JK; Fichna J
J Pharmacol Exp Ther; 2014 Jul; 350(1):69-78. PubMed ID: 24891526
[TBL] [Abstract][Full Text] [Related]
9. Salvinorin A reduces neuropathic nociception in the insular cortex of the rat.
Coffeen U; Canseco-Alba A; Simón-Arceo K; Almanza A; Mercado F; León-Olea M; Pellicer F
Eur J Pain; 2018 Feb; 22(2):311-318. PubMed ID: 28975684
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of salvinorin A on endotoxin-induced hypermotility and neurogenic ion transport in mouse ileum.
Fichna J; Dicay M; Hirota SA; Traboulsi D; Macdonald JA; Janecka A; Beck PL; Zjawiony JK; Macnaughton WK; Storr MA
Neurogastroenterol Motil; 2011 Jun; 23(6):583-e212. PubMed ID: 21414104
[TBL] [Abstract][Full Text] [Related]
11. Anti-inflammatory action of a novel orally available peptide 317 in mouse models of inflammatory bowel diseases.
Sobczak M; Zakrzewski PK; Cygankiewicz AI; Mokrowiecka A; Chen C; Sałaga M; Małecka-Panas E; Kordek R; Krajewska WM; Fichna J
Pharmacol Rep; 2014 Oct; 66(5):741-50. PubMed ID: 25149976
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory effect of cannabinoid agonist WIN55, 212 on mouse experimental colitis is related to inhibition of p38MAPK.
Feng YJ; Li YY; Lin XH; Li K; Cao MH
World J Gastroenterol; 2016 Nov; 22(43):9515-9524. PubMed ID: 27920472
[TBL] [Abstract][Full Text] [Related]
13. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
[TBL] [Abstract][Full Text] [Related]
14. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium.
Kimball ES; Schneider CR; Wallace NH; Hornby PJ
Am J Physiol Gastrointest Liver Physiol; 2006 Aug; 291(2):G364-71. PubMed ID: 16574988
[TBL] [Abstract][Full Text] [Related]
15. Preventive and therapeutic oral administration of the pentacyclic triterpene α,β-amyrin ameliorates dextran sulfate sodium-induced colitis in mice: the relevance of cannabinoid system.
Matos I; Bento AF; Marcon R; Claudino RF; Calixto JB
Mol Immunol; 2013 Jul; 54(3-4):482-92. PubMed ID: 23454360
[TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory and antinociceptive action of the dimeric enkephalin peptide biphalin in the mouse model of colitis: new potential treatment of abdominal pain associated with inflammatory bowel diseases.
Sobczak M; Pilarczyk A; Jonakowski M; Jarmuż A; Sałaga M; Lipkowski AW; Fichna J
Peptides; 2014 Oct; 60():102-6. PubMed ID: 25151037
[TBL] [Abstract][Full Text] [Related]
17. Melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, attenuates TNBS-induced colitis in mice.
Zielińska M; Jarmuż A; Sałaga M; Kordek R; Laudon M; Storr M; Fichna J
Naunyn Schmiedebergs Arch Pharmacol; 2016 May; 389(5):511-9. PubMed ID: 26899972
[TBL] [Abstract][Full Text] [Related]
18. Ultrapotent effects of salvinorin A, a hallucinogenic compound from Salvia divinorum, on LPS-stimulated murine macrophages and its anti-inflammatory action in vivo.
Aviello G; Borrelli F; Guida F; Romano B; Lewellyn K; De Chiaro M; Luongo L; Zjawiony JK; Maione S; Izzo AA; Capasso R
J Mol Med (Berl); 2011 Sep; 89(9):891-902. PubMed ID: 21499737
[TBL] [Abstract][Full Text] [Related]
19. CCL2 (pM levels) as a therapeutic agent in Inflammatory Bowel Disease models in mice.
Maharshak N; Hart G; Ron E; Zelman E; Sagiv A; Arber N; Brazowski E; Margalit R; Elinav E; Shachar I
Inflamm Bowel Dis; 2010 Sep; 16(9):1496-504. PubMed ID: 20222120
[TBL] [Abstract][Full Text] [Related]
20. Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents.
Braida D; Capurro V; Zani A; Rubino T; Viganò D; Parolaro D; Sala M
Br J Pharmacol; 2009 Jul; 157(5):844-53. PubMed ID: 19422370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
